NCT05874401 2025-09-04Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving TopotecanPharmacosmos A/SPhase 4 Recruiting302 enrolled
NCT05071703 2023-10-06Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world StudyJiangsu Simcere Pharmaceutical Co., Ltd.Phase 4 Completed30 enrolled